EyePoint Pharmaceuticals, Inc.

NasdaqGM EYPT

EyePoint Pharmaceuticals, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2024: -38.58%

EyePoint Pharmaceuticals, Inc. Return on Capital Employed (ROCE) is -38.58% for the Trailing 12 Months (TTM) ending September 30, 2024, a 53.20% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

EyePoint Pharmaceuticals, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2023 was -82.44%, a -132.19% change year over year.
EyePoint Pharmaceuticals, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2022 was -35.51%, a -2.72% change year over year.
EyePoint Pharmaceuticals, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2021 was -34.57%, a 33.45% change year over year.
EyePoint Pharmaceuticals, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2020 was -51.95%, a 35.50% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

NasdaqGM: EYPT

EyePoint Pharmaceuticals, Inc.

CEO	Dr. Jay S. Duker M.D.
IPO Date	Jan. 27, 2005
Location	United States
Headquarters	480 Pleasant Street
Employees	121
Sector	Health Care
Industries Pharmaceuticals Eyewear

Description

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Key trends

Past 5 years